Auro-Cyclobenzaprine

Quick links

Choose a section

Quick links to important sections

Advertisements

Auro-Cyclobenzaprine

Advertisements
Advertisements

Method of action: Miorelaxant, Muscle Relaxant

Advertisements

Overview of Auro-Cyclobenzaprine

Auro-Cyclobenzaprine is a prescription medication used for the short-term management of painful muscle spasms. It is defined by its active component, its unique pharmacological classification, and its central role in addressing muscle overactivity following acute musculoskeletal conditions.

Property Description
Active Ingredient Cyclobenzaprine Hydrochloride
Form Tablet (immediate-release)
Pharmacological Class Centrally Acting Skeletal Muscle Relaxant
General Purpose Relief of involuntary muscle spasm
Origin Synthetic (Tricyclic amine derivative)

What Type of Medicine is Auro-Cyclobenzaprine?

Auro-Cyclobenzaprine is classified as a centrally acting skeletal muscle relaxant, a designation based on its influence on the central nervous system. This drug is exclusively a prescription-only item. Its classification emphasizes that its primary pharmacological activity occurs within the CNS, differentiating it from agents that act directly on muscle fibers. The drug is indicated as an adjunct to rest and physical therapy. This confirms the medicine is intended to complement, not replace, physical treatments for conditions like back strain, representing a typical use scenario.

Composition and Formulation: The Active Ingredient

The essential component of Auro-Cyclobenzaprine is the active ingredient, Cyclobenzaprine Hydrochloride. This compound is a synthetic tricyclic amine salt, delivered via the oral route as an immediate-release tablet. The Auro-Cyclobenzaprine product is specifically manufactured by Auro Pharma Inc. and contains the identical active ingredient found in other popular formulations. Structurally, Cyclobenzaprine Hydrochloride shares characteristics with tricyclic antidepressants, a similarity that informs its property as a central nervous system (CNS) depressant. As a pharmaceutical preparation, the active compound is formulated using solid pharmaceutical excipients to ensure its proper delivery into the system.


General Purpose: Relief of Muscle Spasm

The general therapeutic purpose of Auro-Cyclobenzaprine is to provide comfort by reducing the intensity of muscle spasm associated with acute musculoskeletal conditions. By targeting the nerve impulses that cause muscles to involuntarily tighten, the medication helps facilitate muscle relaxation. This action provides relief from local pain and tenderness, which is highly beneficial when integrated into a short-term therapeutic plan.

Regulatory References

  1. Cyclobenzaprine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Auro-Cyclobenzaprine?

Possible side effects and safety information

The safety profile for Auro-Cyclobenzaprine (Cyclobenzaprine Hydrochloride) is officially documented based on its classification as a centrally acting skeletal muscle relaxant with structural similarities to tricyclic compounds. Safety data is organized by frequency and the body system affected, according to regulatory standards.

Adverse Reactions and Frequency

The most Common adverse reactions documented in official labeling typically involve the central nervous system (CNS) and anticholinergic effects. These are often reported as being most frequent at the start of treatment and may include drowsiness, dry mouth, dizziness, fatigue, and headache. Other common gastrointestinal effects include constipation and nausea.

Infrequent or rare adverse reactions are documented across various systems, including psychiatric disorders (e.g., confusion, nervousness, insomnia) and ocular disorders (e.g., blurred vision).

Serious Safety Considerations and Constraints

Regulatory documents highlight the potential for Serious Adverse Reactions, including Serotonin Syndrome, particularly when the medicine is used concurrently with other serotonergic agents. Severe cardiovascular events, such as arrhythmias and stroke, have also been reported, reflecting the drug's structural class.

Specific Safety Constraints and Contraindications are in place. The medication must not be used in patients with hyperthyroidism, during the acute recovery phase of myocardial infarction, or in those with heart block or congestive heart failure. It is also contraindicated for use with or within 14 days of discontinuing Monoamine Oxidase Inhibitors (MAOIs).

Official safety notes advise caution in older adults and individuals with hepatic impairment due to increased susceptibility to adverse effects and elevated drug exposure, respectively. The medication is officially indicated only for short-term use.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Auro-Cyclobenzaprine (cyclobenzaprine hydrochloride) is structurally related to tricyclic antidepressants, and overdose can present with serious, potentially life-threatening symptoms, particularly affecting the cardiovascular and central nervous systems.

Immediate Medical Attention is Required in all cases of suspected overdose. Do not wait for symptoms to worsen. Call emergency medical services immediately if the individual has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened.

Commonly reported manifestations of an overdose include severe drowsiness, confusion, agitation, dizziness, and fast or irregular heartbeats (tachycardia). Gastrointestinal symptoms such as nausea and vomiting are also frequently noted. Ataxia (loss of muscle coordination), tremors, and hallucinations may occur.

Less frequent but more severe complications can include cardiac arrest, cardiac dysrhythmias, a significant drop in blood pressure (severe hypotension), seizures, and coma. The development of Serotonin Syndrome is a critical risk, especially when the drug is combined with other serotonergic agents (such as certain antidepressants). Symptoms of this syndrome can include mental status changes (e.g., agitation, hallucinations), autonomic instability (e.g., fast heart rate, high or unstable blood pressure, excessive sweating), and neuromuscular issues (e.g., muscle stiffness, hyperreflexia).

Risk of serious overdose is potentially greater in the elderly population and when cyclobenzaprine is mixed with other central nervous system depressants, including alcohol. Management of an overdose typically requires hospital-based supportive care, cardiac monitoring, and treatment of specific symptoms and complications.

Advertisements

Therapeutic Uses of Auro-Cyclobenzaprine

Auro-Cyclobenzaprine is commonly used to help with symptoms of increased neurological or muscular activity associated with conditions characterized by periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed, primarily for symptoms related to physical discomfort.


Managing Acute Muscle Spasm and Pain

The medication is applied in addressing symptom clusters that may become intense or disruptive, especially symptoms related to physical discomfort and symptoms that interfere with daily functioning. It is considered relevant for easing manifestations linked to conditions presenting with acute episodes and applied in clinical settings that involve acute or unstable symptom patterns. It is also considered relevant in contexts involving heightened systemic burden.


Supporting Functional Recovery and Mobility

The medication may assist with managing symptoms that interfere with daily functioning and symptoms related to heightened physiological activity. The medication is relevant when supportive symptom management is appropriate, as it supports general well-being during symptomatic phases alongside rest and physical therapy. This role supports patients during episodes of heightened discomfort and provides support that helps ease the overall symptom burden.

“The drug is used to help manage symptoms when acute manifestations interfere with function, providing support that helps ease the overall symptom load.”

Quick Fact: Relief for Acute Muscle Spasm

Advertisements

Eligibility and Restrictions for Use

Eligibility for Auro-Cyclobenzaprine Use

Official regulatory documents define specific populations that are eligible, restricted, or strictly contraindicated (must not use) for Auro-Cyclobenzaprine.


Who Must Not Use This Medicine (Contraindications)

Use of Auro-Cyclobenzaprine is strictly prohibited if you have:

  • A known hypersensitivity or allergy to any component of the drug.
  • Used Monoamine Oxidase (MAO) inhibitors within the last 14 days.
  • Specific cardiovascular conditions, including the acute recovery phase of a heart attack (myocardial infarction), certain arrhythmias, heart block, conduction disturbances, or congestive heart failure.
  • Hyperthyroidism (an overactive thyroid gland).

Age and Health Restrictions

  • Age: The safety and effectiveness of the immediate-release formulation are not established for use in children younger than 15 years of age. Use in the elderly (65 years and older) is generally not recommended due to increased side effects and higher drug levels in the blood.
  • Liver Function: The medicine is not recommended for patients with moderate to severe hepatic (liver) impairment. Use in patients with mild impairment requires caution.
  • Pregnancy and Lactation: Use during pregnancy is only advised if clearly needed. Caution is recommended for nursing mothers as it is unknown if the drug passes into human milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Auro-Cyclobenzaprine's official interaction profile is structured around mandated restrictions and pharmacodynamic concerns documented in regulatory sources.

The most critical restriction is the contraindication with Monoamine Oxidase Inhibitors (MAOIs), which is explicitly prohibited due to the risk of severe reactions, including hyperpyretic crisis and seizures. The official labeling requires a 14-day timing rule, mandating that MAOIs must be discontinued for a minimum of two weeks before treatment with cyclobenzaprine can begin.

Interaction with other medicines is primarily defined by additive pharmacological effects. Co-administration with Serotonergic Agents (including certain antidepressants) may lead to the development of a potentially life-threatening Serotonin Syndrome. The effects of Central Nervous System ( CNS) Depressants, such as Alcohol (Ethanol) and barbiturates, may be enhanced, resulting in increased CNS depression. Additive effects also occur with Anticholinergic Medications.

The regulatory profile further notes population-specific restrictions tied to drug clearance. Because of officially documented reduced clearance leading to increased plasma exposure, use is not recommended in patients with moderate to severe hepatic impairment. Similarly, use of the extended-release formulation is not recommended for geriatric patients due to the possibility of higher blood levels.

This structure confirms that official documentation defines the product’s use through high-severity prohibitions and specific cautions related to combined pharmacological action and altered drug exposure.

Advertisements

Mechanism of Action

Central Modulation of Skeletal Muscle Tone

Auro-Cyclobenzaprine primarily exerts its action as an antagonist (blocker) on serotonin 5-HT2A receptors, particularly within the brainstem's reticular formation. This interaction modulates the activity of descending serotonergic pathways. The resulting signal interference reduces the flow of excitatory impulses to the spinal cord, thereby diminishing the excitability of alpha-motor neurons. This core mechanism leads directly to a diminished intensity of central signaling that contributes to muscle hypertonia.

Secondary Receptor Engagement and Systemic Effects

The drug also engages in antagonistic interactions with other receptor types, including norepinephrine alpha1-adrenergic receptors, histamine H1 receptors, and muscarinic acetylcholine receptors. While these interactions are not responsible for modulating motor neuron excitability, they are integral to the drug's overall pharmacodynamic profile. This secondary engagement results in CNS depression (via H1 antagonism) and peripheral nervous system suppression (via muscarinic antagonism), which are predictable systemic consequences of the drug's broad receptor activity.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Auro-Cyclobenzaprine — Administration Guidelines

This map formalizes the explicit instructions for administering Auro-Cyclobenzaprine immediate-release tablets.


Administration Scope

Instruction Entity Guideline
Route of administration Oral (by mouth).
Dosing schedule (Adult) Initial dose is 5 mg three times a day (t.i.d.). The dose may be increased to 10 mg t.i.d.; maximum daily dose is 30 mg.
Timing in relation to meals The tablet may be administered with or without food.
Preparation requirements None; the immediate-release tablet is intended to be swallowed whole.
Age-group administration rules Approved for use in patients 15 years of age and older. Older adults should start with 5 mg and consider less frequent dosing and slower upward titration.
Missed-dose rules If a dose is missed, the patient should skip that dose and resume the regular dosing schedule; the dose should not be doubled.
Special procedural conditions Use is not recommended for patients with moderate to severe hepatic impairment.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral delivery (immediate-release tablet).
Frequency pattern Three times daily (t.i.d.) usage pattern.
Use-context constraints Treatment must be limited to short periods, specifically up to two or three weeks.

Resulting Procedural Structure

Step sequence:

  • Take the immediate-release tablet orally three times per day (t.i.d.).
  • Swallow the tablet whole, independent of meals.
  • Limit the total duration of treatment to a maximum of two or three weeks.
  • Adjust the starting dose to 5 mg for older adults or those with mild hepatic impairment.

Connection to the overall use protocol (2–4 sentences): The administration parameters define a time-bound and frequency-specific protocol for cyclobenzaprine, mandating oral administration at three distinct intervals daily. The instructions define a strict maximum duration of two to three weeks and specify dose reductions for vulnerable populations, thereby formalizing a controlled, short-term treatment regimen.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence: Cyclobenzaprine

Clinical evidence regarding the compound cyclobenzaprine, the active component in Auro-Cyclobenzaprine, primarily focuses on its use in the short-term management of muscle spasm associated with acute, painful musculoskeletal conditions. The duration of most trials reflects the drug's intended use for periods not exceeding two or three weeks.


Research on Muscle Spasm

Studies have examined whether cyclobenzaprine is associated with differences in pain and stiffness scores compared to placebo. A meta-analysis of multiple randomized controlled trials found differences in patient-reported global assessment of change and pain relief, most notably within the first week of treatment. Research has also explored the compound's use in combination with rest and physical therapy, focusing on patients with acute, localized muscle injuries.


Pharmacologic Action

Cyclobenzaprine's primary action involves effects within the central nervous system (CNS) at the brain stem, specifically the locus coeruleus. Its clinical effects are thought to result from a reduction in tonic somatic motor activity, which influences motor neurons by acting on descending noradrenergic tracts.


Comparative Findings

Comparative studies have evaluated the compound against other non-benzodiazepine muscle relaxants in terms of effects on muscle spasm symptoms. Findings have varied across different patient populations and study designs. In general, differences in efficacy measures are often compared against tolerability profiles and the incidence of dose-related adverse events, particularly central nervous system depression.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Auro-Cyclobenzaprine (FAQ)


Q: Can I take Auro-Cyclobenzaprine with Tylenol or Advil for pain?

Official labeling for cyclobenzaprine, the active ingredient, does not list specific drug interactions with commonly used over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen (Advil). However, studies have shown that when cyclobenzaprine is taken with similar medications, it may increase the risk of side effects, particularly drowsiness. Refer to the official product instructions or labeling for comprehensive interaction information.

Q: How should I dispose of unused Auro-Cyclobenzaprine tablets?

Official guidelines outline recommended disposal methods, such as utilizing a drug take-back program. If a take-back program is not available, the FDA suggests mixing the tablets with an unappealing substance, like coffee grounds, sealing the mixture in a container, and placing it in household trash. This medicine should generally not be flushed down the toilet.

Q: Can I drink alcohol while taking Auro-Cyclobenzaprine?

Official product information advises against the concurrent use of alcohol with this medicine. Cyclobenzaprine can enhance the effects of alcohol, as both substances act as Central Nervous System (CNS) depressants. Combining them may result in significantly increased drowsiness or sedation and can greatly impair physical and mental abilities.

Q: How long until I feel the muscle-relaxing effects?

Official clinical data suggests that the intended relief of muscle spasm is typically observed within the first week of use. The improvement manifests as a reduction in muscle spasm and its associated symptoms, such as pain and limited motion. Side effects like drowsiness, however, may be experienced sooner.

Q: Is Auro-Cyclobenzaprine addictive or habit-forming?

Official regulatory agencies do not classify cyclobenzaprine as a controlled substance, meaning it does not carry the same risk for physical addiction as certain other pain medications. However, official product information notes that following prolonged use, abrupt discontinuation may lead to symptoms such as nausea, headache, or malaise (a general feeling of being unwell).

Q: Can I drive or operate machinery while taking this medicine?

Official warnings note that the medication can impair the performance of hazardous tasks. Because drowsiness and dizziness are common side effects, the medicine may impair the mental and physical abilities needed to safely operate machinery or drive a car.

Q: Does this medicine treat chronic muscle pain or only acute spasms?

The medicine is officially indicated for the relief of muscle spasm associated with acute musculoskeletal conditions. The labeling specifies that use should be limited to short periods, typically up to two or three weeks, as efficacy for more prolonged, chronic use has not been established.

Advertisements

How should Auro-Cyclobenzaprine be stored and disposed of?

How to Store and Dispose of Auro-Cyclobenzaprine

Storage and disposal of Auro-Cyclobenzaprine (Cyclobenzaprine Hydrochloride Tablets) must adhere to official regulatory requirements to maintain product stability and ensure safety.

Storage and Stability

Requirement Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Container Dispense in a tight, light-resistant container and keep tightly closed.
Protection Protect from light; storage outside the designated temperature range is prohibited.

Safety and Disposal

The medicine must be stored with a child-resistant closure and kept strictly out of the reach and sight of children. Any unused, expired, or unwanted tablets must be disposed of according to local municipal or government regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Auro-Cyclobenzaprine found in:

A-Z Index: